- Significant Reduction in Dermatitis
Severity Demonstrated
NAPLES, Fla., Nov. 18, 2021 /PRNewswire/ - Enveric
Biosciences (NASDAQ: ENVB) ("Enveric" or the
"Company"), a patient-centric biotechnology company developing
next-generation mental health and cancer support care therapies by
leveraging psychedelic-derived molecules for the mind and synthetic
cannabinoids for the body, today announced that EV102, the
Company's cannabidiol (CBD) based product in development for
topical prescription treatment of radiodermatitis, has demonstrated
significant and meaningful reduction in dermatitis severity, skin
redness, and duration in a preclinical rodent model.
"Cancer patients around the world suffer the harsh side effects
of various anti-cancer treatments," said Dr. Joseph Tucker, CEO of Enveric Biosciences.
"Radiodermatitis, the most common side effect of radiation therapy,
is a physical skin irritation with symptoms ranging from red rash
to open wounds. EV102 was topically applied during a daily
treatment regimen and resulted in a nearly 50% reduction in redness
scoring severity. Similar results were obtained for overall
dermatitis severity, which includes desquamation (skin peeling) and
ulceration as part of a composite score. Extending these
promising results was an observed reduction in overall duration of
dermatitis symptoms." The significance of these preclinical
findings will be evaluated in a planned human evaluation in
2022.
"At Enveric, we are focused on improving quality of life for
cancer patients. The encouraging results of EV102 positions us to
take the next steps in bringing safer and more effective
prescription treatment options to market. We expect results from
the preclinical study to support our efforts to move EV102 to a
Phase I clinical study, targeted to begin in the second half of
2022," concluded Dr. Tucker.
Radiodermatitis (also called radiation dermatitis) is a
condition caused by the high-energy X-rays delivered during
radiation therapy. It affects nearly 95% of patients who receive
radiation for cancer treatment, with approximately 85% of patients
having moderate-to-severe skin reactions. Radiodermatitis usually
begins to occur within 1-4 weeks of treatment and persists for the
duration of radiation therapy. The severity of the skin reactions
ranges from mild erythema (red rash) to dry desquamation (itchy,
peeling skin) to the more severe moist desquamation (open wound)
and severe ulceration. Radiodermatitis can be similar to the
discomfort of a mild-to-severe sunburn: painful, difficult to move
or wear clothing, itching, and peeling skin. In the most severe
cases, ulceration can occur, disrupting the treatment.
About Enveric Biosciences
Enveric
Biosciences (NASDAQ: ENVB) is an innovative biotechnology
company developing a next-generation mental health and oncology
treatment clinical discovery platform, leveraging
psychedelic-derived molecules for the mind and synthetic
cannabinoids for the body. Enveric's robust pipeline supports drug
development from the clinic to commercialization for millions of
patients in need around the world suffering from conditions that
include cancer-related distress, PTSD and more. For more
information, please visit www.enveric.com.
Forward-Looking Statements
This press release contains
forward-looking statements and forward-looking information within
the meaning of applicable securities laws. These statements relate
to future events or future performance. All statements other than
statements of historical fact may be forward-looking statements or
information. Generally, forward-looking statements and information
may be identified by the use of forward-looking terminology such as
"plans", " expects" or "does not expect", "proposed", "is
expected", "budgets", "scheduled", "estimates", "forecasts",
"intends", "anticipates" or "does not anticipate", or "believes",
or variations of such words and phrases, or by the use of words or
phrases which state that certain actions, events or results may,
could, would, or might occur or be achieved. Forward-looking
statements consist of statements that are not purely historical,
including any statements regarding beliefs, plans, expectations, or
intentions regarding the future. Such forward-looking statements
are based on the beliefs of management as well as assumptions made
by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including, but not limited to, the ability to achieve the value
creation contemplated by technical developments; the impact of the
novel coronavirus (COVID-19) on Enveric's ongoing and planned
clinical trials; the geographic, social and economic impact of
COVID-19 on Enveric's ability to conduct its business and raise
capital in the future when needed; delays in planned clinical
trials; the ability to establish that potential products are
efficacious or safe in preclinical or clinical trials; the ability
to establish or maintain collaborations on the development of
therapeutic candidates; the ability to obtain appropriate or
necessary governmental approvals to market potential products; the
ability to obtain future funding for developmental products and
working capital and to obtain such funding on commercially
reasonable terms; Enveric's ability to manufacture product
candidates on a commercial scale or in collaborations with third
parties; changes in the size and nature of competitors; the ability
to retain key executives and scientists; and the ability to secure
and enforce legal rights related to Enveric's products, including
patent protection. A discussion of these and other factors,
including risks and uncertainties with respect to Enveric, is set
forth in Enveric's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any
intention or obligation to revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/enveric-biosciences-announces-positive-preclinical-data-for-ev102-radiodermatitis-drug-candidate-301427624.html
SOURCE Enveric Biosciences